UBS Group Issues Positive Forecast for Kenvue (NYSE:KVUE) Stock Price

by · The Markets Daily

Kenvue (NYSE:KVUE – Get Free Report) had its price target hoisted by investment analysts at UBS Group from $19.00 to $20.00 in a research note issued to investors on Monday, Benzinga reports. The firm currently has a “neutral” rating on the stock. UBS Group‘s price target would suggest a potential upside of 3.04% from the stock’s current price.

A number of other research analysts have also recently commented on the stock. Zacks Research cut shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. HSBC dropped their price target on shares of Kenvue from $20.00 to $19.00 and set a “hold” rating on the stock in a research note on Monday, August 10th. Barclays boosted their price objective on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 21st. Weiss Ratings reissued a “hold (c)” rating on shares of Kenvue in a research report on Friday, September 11th. Finally, Wall Street Zen downgraded Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Thirteen research analysts have rated the stock with a Hold rating. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $19.44.

Check Out Our Latest Report on KVUE

Kenvue Stock Up 0.5%

Shares of NYSE KVUE traded up $0.10 on Monday, hitting $19.41. The company had a trading volume of 66,595,389 shares, compared to its average volume of 20,937,440. The company has a quick ratio of 0.71, a current ratio of 1.01 and a debt-to-equity ratio of 0.67. Kenvue has a 12-month low of $14.06 and a 12-month high of $20.13. The firm has a market capitalization of $37.28 billion, a P/E ratio of 22.06, a PEG ratio of 1.78 and a beta of 0.48. The business has a 50 day moving average of $18.40 and a two-hundred day moving average of $18.19.

Kenvue (NYSE:KVUE – Get Free Report) last announced its earnings results on Friday, October 30th. The company reported $0.29 EPS for the quarter, meeting the consensus estimate of $0.29. The business had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.86 billion. Kenvue had a return on equity of 21.52% and a net margin of 10.88%. The company’s revenue was up 3.2% on a year-over-year basis. During the same period last year, the business posted $0.28 EPS. As a group, equities research analysts forecast that Kenvue will post 1.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Johnson Financial Group Inc. acquired a new position in shares of Kenvue in the 2nd quarter valued at about $26,000. CoreCap Advisors LLC boosted its stake in Kenvue by 64.9% during the 2nd quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock valued at $29,000 after purchasing an additional 591 shares during the period. GK Wealth Management LLC bought a new position in Kenvue in the 3rd quarter worth about $27,000. Bell Investment Advisors Inc bought a new position in Kenvue in the 2nd quarter worth about $35,000. Finally, Keating Financial Advisory Services Inc. acquired a new stake in shares of Kenvue in the second quarter valued at approximately $38,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Company Profile

(Get Free Report)

Kenvue Inc is a consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, and essential health products, serving consumers through retail, e-commerce and other distribution channels.

The company’s brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; and Listerine, Johnson’s and OGX in oral care, baby care and hair care.

Further Reading